Search

Search Constraints

You searched for: Author/Creator Subbiah, V

Search Results

2. Selective RET kinase inhibition for patients with RET-altered cancers. (18th April 2018)

3. 71OPhase I extension study of ETC-159 an oral PORCN inhibitor administered with bone protective treatment, in patients with advanced solid tumours. (25th November 2018)

4. 105PDetection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. (23rd October 2018)

5. 363OTreatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). (24th November 2019)